DexCom, Inc. $DXCM Shares Sold by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. cut its stake in DexCom by 45.1% in Q4, selling 85,745 shares and leaving it with 104,172 shares valued at about $6.9 million.
• Other institutions moved aggressively—Vanguard, CIBC, Holocene and others added large positions—leaving hedge funds and institutional investors owning about 97.75% of DexCom stock.
• DexCom recently beat quarterly expectations (EPS $0.68 vs. $0.65) with revenue up 13.1% to $1.26B; analysts’ consensus is a "Moderate Buy" with an average price target of $86.50.

Robeco Institutional Asset Management B.V. lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 45.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,172 shares of the medical device company's stock after selling 85,745 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in DexCom were worth $6,914,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of DXCM. Holocene Advisors LP purchased a new stake in shares of DexCom during the third quarter worth about $163,964,000. CIBC Private Wealth Group LLC increased its stake in shares of DexCom by 374.3% during the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company's stock worth $195,666,000 after purchasing an additional 2,294,709 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of DexCom by 2.3% during the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company's stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares in the last quarter. DSM Capital Partners LLC increased its stake in shares of DexCom by 76.5% during the third quarter. DSM Capital Partners LLC now owns 2,533,539 shares of the medical device company's stock worth $170,482,000 after purchasing an additional 1,098,243 shares in the last quarter. Finally, Iron Triangle Partners LP purchased a new stake in shares of DexCom during the third quarter worth about $57,196,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the sale, the executive vice president owned 112,904 shares of the company's stock, valued at $7,321,824.40. This represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.32% of the stock is currently owned by company insiders.

DexCom Stock Down 2.2%

Shares of NASDAQ DXCM opened at $61.54 on Thursday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The stock has a market cap of $23.68 billion, a PE ratio of 29.30, a P/E/G ratio of 1.23 and a beta of 1.55. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average of $67.65 and a 200 day moving average of $66.79.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion during the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the prior year, the company earned $0.45 EPS. DexCom's revenue was up 13.1% compared to the same quarter last year. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on DXCM shares. Truist Financial reissued a "buy" rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Morgan Stanley reissued an "overweight" rating on shares of DexCom in a research note on Monday, January 12th. Citigroup upped their price objective on shares of DexCom from $77.00 to $84.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Evercore raised shares of DexCom from an "in-line" rating to an "outperform" rating and set a $90.00 price objective for the company in a research note on Tuesday, March 24th. Finally, Canaccord Genuity Group set a $95.00 price objective on shares of DexCom and gave the company a "buy" rating in a research note on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $86.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.